Boditech Media
-
PRESS RELEASE
Boditech Med Reports Operating Profit of 7.15 Million USD in Q2 2024, Up 13% Year-on-Year
Sales reached 27.85 million USD (36.2 billion KRW) with an operating profit of 7.15 million USD (9.3 billion KRW) in Q2 2024
-
PRESS RELEASE
Boditech Med Signs MOU with Taiwan's BPM for Diabetic Kidney Disease Prediction Marker
MOU signed for the license of diabetic kidney disease prediction marker 'DNlite-IVD103'.
-
PRESS RELEASE
Boditech Med, Q1 2024 Sales Reach $21.6 Million (33.1 Billion Won) ... Up 12.3% YoY
Consolidated sales for Q1 2024 amounted to $21.6 million (33.1 billion won), with operating profit recorded at $4.2 million (5.9 billion won).
-
PRESS RELEASE
Boditech Med Acquires 3.03% Stake in 4TEEN4, a German Developer of Products for Cardiogenic Shock
Planned launch of DPP3 on-site diagnostic products, capable of predicting myocardial infarction shock progression, expected within this year
-
NEWS
Performance Validation of Boditech Med's AFIAS D-dimer in Thrombosis Research Journal
Superiority Demonstrated in Capillary Whole Blood and Venous Plasma Correlation Analysis
-
PRESS RELEASE
Boditech Med, Obtains Export Permit for the Biomarker 'PenKid' for Acute Kidney Injury Diagnosis
Obtained an Export Permit for PenKid, which enables a rapid diagnosis of acute kidney injury within 15 minutes
-
PRESS RELEASE
Boditech Med Obtains Emergency Use Authorization (EUA) for COVID-19 Home Test Kit from US FDA
Through its U.S. subsidiary, Immunostics, Boditech Med obtains emergency use authorization for COVID-19 home test kits.
-
PRESS RELEASE
Boditech Med and Joinstar, Agreement for Chronic Disease Diagnosis in China
Joinstar will be supplied with key components of cartridges used in chronic disease diagnosis.
-
PRESS RELEASE
Boditech Med, LAMEDITECH, 'HandyRay' Enter Global Sales Agreement
HandyRay is the domestic unique produced laser blood collection device specialized in peripheral blood collection using laser technology in Korea.
-
PRESS RELEASE
Boditech Med has entered the second stage of distributing a pharmacy diagnosis system with RD Group
Planning to supply the AFIAS platform to 2,700 pharmacies owned by RD Group